News thumbnail
Health / Thu, 19 Nov 2026 Nature

Development and characterization of α-Mangostin-loaded polymeric nanoparticles for intranasal brain delivery: pharmacokinetic evaluation and preliminary in-vitro neuroprotective assessment

The present study aimed to develop αM-loaded polymeric nanoparticles for a intranasal delivery and improved brain availability. The optimized αM-PNPs (polylactide-co-glycolide as PLGA nanoparticles) were characterized using the physicochemical, in-vitro, and ex-vivo evaluations, followed by long-term stability studies. The αM-PNPs exhibited a biphasic drug release profile, with approximately 88% cumulative drug release over 12 h. However, based on the reported regression coefficients​, the release profile was best fitted to first-order and Hixson-Crowell models (r² = 0.9976). The optimized αM-PNPs demonstrated a satisfactory long-term stability under the controlled storage conditions. αM-PNPs showed enhanced brain drug availability and improved in vitro cytoprotective activity (BV-2) as compared to αM-SUS.

α-Mangostin (αM) belongs to a bioactive xanthone derivative, having antioxidant​ and potential neuroprotective properties. However, its therapeutic applications are restricted due to limited aqueous solubility and limited penetration across the blood-brain barrier (BBB) of the brain. The present study aimed to develop αM-loaded polymeric nanoparticles for a intranasal delivery and improved brain availability. αM was initially selected through a multiscale in-silico studies. The optimized αM-PNPs (polylactide-co-glycolide as PLGA nanoparticles) were characterized using the physicochemical, in-vitro, and ex-vivo evaluations, followed by long-term stability studies. In vivo pharmacokinetics were conducted in rats and a preliminary neuroprotective activity was evaluated in OGD/R-induced BV-2 cells. The in-silico analysis showed a favorable docking score (-9.980 kcal/mol) for αM and formed a stable complex with the PPAR-γ receptor throughout a 200ns MD simulation, supporting its predicted interaction with PPAR-γ. The optimized αM-PNPs exhibited a mean particle size of 232.63 ± 5.03 nm, a zeta potential of -20.9 ± 2.27 mV, an encapsulation efficiency (%EE) of 84.7 ± 3.57%, a drug loading (%DL) of 14.5 ± 1.08%, and a polydispersity index (PDI) of 0.191 ± 0.024. The αM-PNPs exhibited a biphasic drug release profile, with approximately 88% cumulative drug release over 12 h. However, based on the reported regression coefficients​, the release profile was best fitted to first-order and Hixson-Crowell models (r² = 0.9976). The steady state permeation flux value (J ss ) of αM-PNPs (573.98 ± 17.1 µg/h.cm2) was relatively higher than αM-SUS (316.8 ± 10.6 µg/h.cm2), demonstrating an intense modulation of the BBB for improved penetration into the brain. The optimized αM-PNPs demonstrated a satisfactory long-term stability under the controlled storage conditions. αM-PNPs showed enhanced brain drug availability and improved in vitro cytoprotective activity (BV-2) as compared to αM-SUS. Overall, the developed intranasal αM-PNPs represent a promising non-invasive strategy for enhancing nose-to-brain delivery of αM.

© All Rights Reserved.